Cost–utility analysis of telemonitoring versus conventional hospital-based follow-up of patients with pacemakers. The NORDLAND randomized clinical trial
Open Access
- 29 January 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (1) , e0226188
Abstract
The aim of our study was to perform an economic assessment in order to check whether or not telemonitoring of users with pacemakers offers a cost-effective alternative to traditional follow-up in outpatient clinics. We used effectiveness and cost data from the NORDLAND trial, which is a controlled, randomized, non-masked clinical trial. Fifty patients were assigned to receive either telemonitoring (TM; n = 25) or conventional monitoring (CM; n = 25) and were followed up for 12 months after the implantation. A cost–utility analysis was performed in terms of additional costs per additional Quality-Adjusted Life Year (QALY) attained from the perspectives of the Norwegian National Healthcare System and patients and their caregivers. Effectiveness was similar between alternatives (TM: 0.7804 [CI: 0.6864 to 0.8745] vs. CM: 0.7465 [CI: 0.6543 to 0.8387]), while cost per patient was higher in the RM group, both from the Norwegian NHS perspective (TM: €2,079.84 [CI: 0.00 to 4,610.58] vs. €271.97 [CI: 158.18 to 385.76]; p = 0.147) and including the patient/family perspective (TM: €2,295.91 [CI: 0.00 to 4,843.28] vs. CM: €430.39 [CI: 0.00 to 4,841.48]), although these large differences—mainly due to a few patients being hospitalized in the TM group, as opposed to none in the CM group—did not reach statistical significance. The Incremental Cost–Effectiveness Ratio (ICER) from the Norwegian NHS perspective (€53,345.27/QALY) and including the patient/caregiver perspective (€55,046.40/QALY), as well as the Incremental Net Benefit (INB), favors the CM alternative, albeit with very broad 95%CIs. The probabilistic analysis confirmed inconclusive results due to the wide CIs even suggesting that TM was not cost-effective in this study. Supplemental analysis excluding the hospitalization costs shows positive INBs, whereby suggesting a discrete superiority of the RM alternative if hospitalization costs were not considered, albeit also with broad CIs. Cost–utility analysis of TM vs. CM shows inconclusive results because of broad confidence intervals with ICER and INB figures ranging from potential savings to high costs for an additional QALY, with the majority of ICERs being above the usual NHS thresholds for coverage decisions. ClinicalTrials.gov NCT02237404.Keywords
Funding Information
- European Economic Area (008/ABELCM/2014A)
- Regional Government of Andalusia (PI/0256/2017)
This publication has 58 references indexed in Scilit:
- Remote monitoring and the twin epidemics of atrial fibrillation and chronic heart failureEP Europace, 2013
- Cost-Utility Analysis of the EVOLVO Study on Remote Monitoring for Heart Failure Patients With Implantable Defibrillators: Randomized Controlled TrialJournal of Medical Internet Research, 2013
- Cost-consequence analysis of daily continuous remote monitoring of implantable cardiac defibrillator and resynchronization devices in the UKEP Europace, 2013
- A randomized study of remote follow-up of implantable cardioverter defibrillators: safety and efficacy report of the ECOST trialEuropean Heart Journal, 2012
- Remote follow-up of pacemakers in a selected population of debilitated elderly patientsEP Europace, 2012
- A randomized trial of long-term remote monitoring of pacemaker recipients (The COMPAS trial)European Heart Journal, 2011
- The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) TrialJACC, 2011
- Optimized post-operative surveillance of permanent pacemakers by home monitoring: the OEDIPE trialEP Europace, 2008
- Remote monitoring of implantable cardioverter defibrillator patients: a safe, time-saving, and cost-effective means for follow-upEP Europace, 2008
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990